Tucatinib promotes immune activation and synergizes with programmed cell death-1 and programmed cell death-ligand 1 inhibition in HER2-positive breast cancer.
J Natl Cancer Inst
; 115(7): 805-814, 2023 07 06.
Article
in En
| MEDLINE
| ID: mdl-37166471
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
B7-H1 Antigen
Type of study:
Prognostic_studies
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
J Natl Cancer Inst
Year:
2023
Type:
Article
Affiliation country:
Australia